U.S. Markets closed

Molecular Profiles to develop psoriasis products for Telormedix

Molecular Profiles, a subsidiary of Columbia Laboratories, has been selected as the formulation development partner for a major pan-European collaborative project. The UK-based company has been chosen by clinical stage biopharmaceutical company Telormedix SA to develop both topical and solid dosage formulations for the use in the treatment of psoriasis. The project, operating under the acronym PAT, or Psoriasis Anti-inflammatory Treatment, will involve other consortium partners Biopta, Midatech Biogune and the University Hospital Zurich. Telormedix raised funding from the European Eurostars Programme to coordinate this international research project for one of its promising drug candidates, TMX-302, which will use Midatech’s glycan-coated gold nanoparticles formulated using Molecular Profiles’ expertise.